Mysimba in Europe

What is Mysimba and how does it work?

If we talk about weight loss trends, Mysimba in Europe is a buzzing name among obese and overweight patients as well as physicians at obesity clinics. Mysimba is an approved drug in European union with two active ingredients as naltrexone hydrochloride and bupropion hydrochloride (strength 7.2 mg naltrexone + 78 mg bupropion). There is an increase in physician prescription that is required to buy Mysimba in Europe. Both of these ingredients in combination work wonders in weight loss by reducing appetite and craving for food and thus decreasing food intake. Due to its effectiveness, Mysimba sale is getting increased day by day.

There are online and offline pharmacies in Europe, from where the patient can buy Mysimba. Some of these pharmacies provide discounts and saving offers also when you buy Mysimba. However, you should beware of fake companies and distributors and buy Mysimba from genuine pharmacies only.

However, regular monitoring of the patient is needed for any changes in vital signs or psychological condition, while taking the drug. There are certain adverse effects as intolerable nausea, headache, constipation, dizziness, dryness of mouth, vomiting, and increase in resting heart rate. Serious neuropsychiatric effects can happen. If the patient has a history of seizures or neuropsychiatric disorder, then stop to buy Mysimba and don’t take this treatment.

Mysimba weight loss pills do not suit everyone. This medicine has been launched specifically for seriously obese and overweight people. If you have a body mass index (BMI) of 27 kg/m2 or higher and one of more specific risk factors such as hypertension or type 2 diabetes, this medicine can be considered for you. Though weight loss is on almost everyone’s wish list, Mysimba is not for those all who are looking to reduce some fat. You need to check before head whether to go for it to buy Mysimba or not. It depends on your present health, past medical history & current medication if any. Mysimba is not recommended if you are:

  • Suffering from heart disease
  • Suffering from uncontrolled hypertension
  • Pregnant
  • Breastfeeding
  • Taking opioid analgesic
  • Taking medication for diabetes
  • History of seizure
  • Taking alcohol withdrawal medicines

Before Mysimba Europe approval, the CHMP (Committee for Medicinal Products for Human Use) in Europe accepted the fact that Mysimba was clinically significant and effective drug for weight loss, although the effectiveness of the drug in accelerating weight loss was limited. When Mysimba approved, CHMP also instructed that patient re-assessment should be done mandatorily after four months of Mysimba intake. This will ensure whether continue to buy Mysimba and administer it to get benefitted OR to stop taking the drug. For safety concerns, CHMP highlighted about possible cardiovascular effects on the heart and blood vessels and a slightly more risk of seizures. CHMP accepted that the most common side effects were manageable.

Administering Mysimba can be stopped if it shows adverse effects. During the assessment, provisional data from an on-going study of cardiovascular outcomes were reviewed. CHMP also recommended that medicine’s cardiovascular effects should be monitored regularly during medication therapy. On the equilibrium of the available evidence, it was decided by the CHMP that Mysimba benefits are more than its adverse effects and risks and recommended that Mysimba is approved for use in the EU. Thus Mysimba is approved by European Medicines agency (EMA) to use as weight loss pill along with low-fat diet and physical exercise. In 2016, Orexigen Therapeutics executed a distribution and commercialization agreement with Ireland and UK. Thus, pharma company made this availability of Mysimba for sale. It will be available in UK and Ireland to buy Mysimba by mid-2017. European medicines agency (EMA) published European public assessment report for Mysimba. This report elaborates benefits and risk factors associated with Mysimba weight loss treatment.

According to WHO statistics, Obesity prevalence has been doubled worldwide if compared to the year 1980 and 2008. As per 2008 reports, more than 50% of men and women are overweight (>27 kg) or obese (>30 kg) in WHO European region. This is an alarming data and though European union is promoting a healthy lifestyle with increased physical activity and low-fat diet, to control obesity, medicinal intervention is needed to effectively treat overweight and obese patients. Mysimba in Europe is one such drug which is approved to be used as weight loss drug in the European union.

Mysimba is manufactured by Orexigen therapeutics Ireland Ltd. It is the trending name in the UK in obesity treatment options these days. Its active ingredients naltrexone and bupropion used independently to treat addiction and depression. When in combination as Mysimba, these molecules act on the brain and reduce cravings and hunger for food. This way, it changes your eating behaviour and reduces calorie intake, thus ultimately reduces body weight.

The bupropion molecule is studied for its therapeutic usage to treat obesity. When clinical trials were done to assess its effects on depressive disorders, it is observed that there is no weight gain in patients treated with bupropion as compared to other patients taking other antidepressant drugs and as compared to placebo. A placebo-controlled study conducted 3 times to evaluate bupropion’s effects on weight loss and it showed demonstrated the effect on weight loss in overweight and obese women as compared to placebo.

It is observed that naltrexone and bupropion in combination work in synergy, independently and having complementary effects, thus impacts food intake and treats obesity.

There is no clinical evidence with overdose with Mysimba. The maximum daily dose of combined administration of bupropion and naltrexone in clinical trials had 50 mg naltrexone hydrochloride and 400 mg bupropion hydrochloride. The most serious clinical implications of combined use of Mysimba overdose are likely related to bupropion.

Though Mysimba is approved by EMA, there are some precautions to take care of, so that a safe and healthy weight loss can be achieved. You need to take care of following when going for weight loss plan with Mysimba:

  • Dose/day is divided & increased gradually.
  • The physician should be aware of total medical history.
  • After 16 weeks of intake, if there is no change in existing weight or waist circumference, then you need to stop taking Mysimba.
  • Read warning message before taking medicine. Mysimba packaging comes with a clear warning message stating it can cause serious side effects of suicidal thoughts or actions.

A sufficient airway, oxygenation, and ventilation should be ensured. vital signs and cardiac rhythm should be monitored. EEG monitoring is also recommended for the first 48 hours post-intake. General symptomatic and supportive measures are also recommended. Induction of emesis is not recommended. Activated charcoal should be administered. There is no experience with the use of forced diuresis, dialysis, hem perfusion, or exchange transfusion in the management of Mysimba overdose. No specific antidotes for Mysimba are known.

Mysimba interacts with certain drugs & disease conditions which can make the condition worst. Hence you should always be aware & inform your physician if you are suffering from any of below-mentioned disease or you are already taking any of these medicines:

  • Drugs: Atorvastatin, clonazepam, cyclobenzaprine, phentermine, tramadol, hydrochlorothiazide, ibuprofen, trazodone, Lisinopril, Vyvanse.
  • Alcohol, nicotine
  • Diseases: Psychosis, Liver diseases, Seizures, glaucoma, mania, renal dysfunction

However, you should not stop taking Mysimba without informing/consulting your doctor who prescribed it.  Obesity can cause life-threatening diseases and can also cause many psychological and physical problems.

Apart from weight loss benefit, there are other benefits to buying Mysimba in Europe such as reduced waist circumference, reduction in dangerous visceral fat, thus reduced the risk of diabetes and cardiovascular diseases. Reduction in LDL (bad cholesterol) and triglycerides while improvement in glycaemic index was observed in diabetic patients.

There are certain side effects of Mysimba which need to be observed early and appropriate measures to be taken to minimize health risk. These side effects are insomnia, anxiety, restlessness, headache, mania, seizures, dizziness, lack of concentration, muscular pain, loss of appetite, constipation, nausea, hot flush. You should contact your doctor or call emergency medical services if any such symptom found. Vital signs should be checked on a regular basis when taking the drug. Buy Mysimba and it will fasten the process of losing weight until you reach a healthy BMI.  Order Mysimba and start a journey towards healthy weight loss.

Mysimba dosage directions are as follows:

  • Week 1: One tablet in the morning
  • Week 2: One tablet in the morning and one tablet in the evening
  • Week 3: Two tablets in the morning and one tablet in the evening
  • Week 4 and onwards: Two tablets in the morning and two tablets in the evening

The maximum recommended a daily dose of Mysimba is two tablets taken twice daily for a total dose of 32 mg naltrexone hydrochloride and 360 mg bupropion hydrochloride.

The patient should be evaluated after 16 weeks and re-evaluated annually. If a dose is missed, you should not take an additional dose, but take the prescribed next dose at the usual time.

Naltrexone/bupropion should be used with caution in patients over 65 years of age and is not recommended in patients over 75 years of age.

Mysimba is contraindicated in patients with end stage renal failure or severe renal impairment and is not recommended in patients with moderate renal impairment.

For individuals who are at more risk for renal impairment, patients with diabetes or elderly individuals estimated glomerular filtration rate should be assessed prior to starting the treatment with Mysimba. bupropion is contraindicated in patients with severe liver impairment. The safety and efficacy of Mysimba for sale in children and adolescents below 18 have not yet been established. Hence, Mysimba should not be used in children and adolescents below 18 years of age.

Disclaimer: The content of this article is for information and awareness purpose only. Do not consider this as a recommendation to take Mysimba therapy.